François Spertini

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Cem Gabay, Bruno Fautrel, Jürgen Rech et al. · Annals of the Rheumatic Diseases · 2018 · 284 citations · Full text

Trace element supplementation modulates pulmonary infection rates after major burns: a double-blind, placebo-controlled trial

Mette M. Berger, François Spertini, Alan Shenkin et al. · American Journal of Clinical Nutrition · 1998 · 221 citations

Acute Lung Injury, Inflammation, Placebo-controlled Trial +6

Research needs in allergy: an EAACI position paper, in collaboration with EFA

Nikolaos G. Papadopoulos, Ioana Agache, Sevim Bavbek et al. · Clinical and Translational Allergy · 2012 · 205 citations · Full text

Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial

François Spertini, R Audran, Reza Chakour et al. · The Lancet Respiratory Medicine · 2015 · 174 citations · Full text

Vaccination, Vaccine Safety, Pulmonary Tuberculosis +8

Down‐regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α–kinoid

Bernard Lauwerys, É. Hachulla, François Spertini et al. · Arthritis & Rheumatism · 2012 · 166 citations